The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Selects 9 Priority Prefectures for Generic Promotion Project, but Leaves Tokyo Out
July 12, 2018
-
REGULATORY MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
-
REGULATORY Tokyo Govt to Launch Support Program for Drug Discovery Startups to Solve Obstacles to Fundraising, IP Strategy
July 10, 2018
-
BUSINESS New Takeda Global Headquarters Designed for LGBT Inclusion
July 9, 2018
-
BUSINESS No Drug Breaks 100 Billion Yen Mark in FY2017 Japan Sales Ranking: Jiho Tally
July 6, 2018
-
BUSINESS Pfizer Wringing Hands over PMP Eligibility for Lorlatinib; It Might Earn 1st Conditional OK, but It’s “4th” ALK Inhibitor
July 5, 2018
-
REGULATORY Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
July 4, 2018
-
TRENDS Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
July 3, 2018
-
REGULATORY MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
July 3, 2018
-
BUSINESS Takeda Celebrates Grand Opening for New Global Headquarters
July 3, 2018
-
BUSINESS With Focus on CGRP, Development of New Generation of Preventive Treatments for Migraines Heating Up
July 2, 2018
-
BUSINESS Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
June 29, 2018
-
BUSINESS Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
-
BUSINESS Keytruda’s MSI-H Cancer Indication to Be Reviewed Under Conditional Early Approval System
June 28, 2018
-
BUSINESS Chugai Chairman Prods Drug Makers to Innovate, Chides Calls for Relaxed Pricing
June 27, 2018
-
ACADEMIA Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
-
BUSINESS Xofluza Likely to Jolt Japan Flu Market This Winter
June 25, 2018
-
BUSINESS Maviret Sweeping Japan Hep C Market, 80% Share Snatched in Just 4 Months?
June 22, 2018
-
ACADEMIA Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
-
TRENDS Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…